New Research Could Transform Diagnostics for Stroke and Cancer Patients
Region Stockholm
A collaboration between KTH Royal Institute of Technology and clinicians from Region Stockholm has led to groundbreaking research that promises to improve the diagnosis and treatment of two of the most critical diseases of our time—stroke and cancer. These advancements have been made possible through funding from the Health, Medicine, and Technology (HMT) research initiative.
“Our primary goal is to detect cancer at an early stage, improving survival rates and saving lives. I hope this innovation becomes a global standard, benefiting millions of patients not just in Sweden, but worldwide,” says Mats Danielsson , Professor of Medical Imaging Physics at KTH.
Fruitful collaboration
Danielsson and his research team at KTH developed a novel silicon-based sensor integrated with circuits for computed tomography (CT). This advanced detector can capture X-rays one by one, offering rapid, high-resolution imaging. Recognizing the potential clinical applications of this technology, the team sought collaboration with a medical expert. A conversation with Staffan Holmin, Professor and Chief Physician at Karolinska University Hospital, marked the beginning of a fruitful partnership.
“My role early on was to assess the clinical relevance of the new detector technology, determining which features would add value to patient care, as well as conducting basic scientific tests on biological materials,” explains Holmin.
For conditions like stroke and cancer, swift and precise diagnosis is vital, with CT scans playing a central role in the care process. The new sensor technology has the potential to streamline diagnostics and improve available treatments. For instance, in stroke cases, removing blood clots that block circulation is a critical procedure pioneered at Karolinska University Hospital, where this innovation could enhance care.
Funding was instrumental
Nearly a decade ago, Danielsson and Holmin applied for HMT research funding to support their idea.
“We formed an excellent team, and the HMT funding was instrumental in helping us develop the concept and bring it to its current stage. The funding has been vital, particularly because it supports projects at the intersection of technology and medicine with clear benefits for patients,” says Danielsson. He adds, “This support has helped establish the foundation for what could grow into a significant industry, both locally and globally.”
The collaboration has progressed to clinical trials, a necessary step toward regulatory approval for patient use. It has also fostered a burgeoning industry encompassing research and manufacturing in the Stockholm region.
“This technology holds the promise of significantly advancing the diagnosis of cardiovascular diseases and cancer. Karolinska was the first institution globally to conduct a clinical trial using this innovation. The initial study included 27 participants, and we recently launched another trial with updated hardware and software, involving approximately 100 participants. I hope our efforts will lead to new methods that enhance patient outcomes in healthcare,” Holmin concludes.
Text: Annelie Englund
